Serum cholinesterase is associated with incident diabetic retinopathy: the Shanghai Nicheng cohort study

[1]  E. Huang,et al.  12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[2]  E. Huang,et al.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[3]  J. Bai,et al.  Ghrelin Ameliorates Diabetic Retinal Injury: Potential Therapeutic Avenues for Diabetic Retinopathy , 2021, Oxidative medicine and cellular longevity.

[4]  A. Bhatwadekar,et al.  Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment , 2021, Clinical interventions in aging.

[5]  D. Shen,et al.  A deep learning system for detecting diabetic retinopathy across the disease spectrum , 2021, Nature Communications.

[6]  J. Stewart,et al.  Sex-Based Analysis of Potential Inflammation-Related Protein Biomarkers in the Aqueous Humor of Patients With Diabetes Mellitus , 2021, Translational vision science & technology.

[7]  Tueng T. Shen,et al.  Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study , 2020, The Lancet. Global health.

[8]  L. Rashed,et al.  Retinoprotective effect of donepezil in diabetic mice involves mitigation of excitotoxicity and activation of PI3K/mTOR/BCl2 pathway. , 2020, Life sciences.

[9]  Fan Hu,et al.  Nomogram-Based Prediction of the Risk of Diabetic Retinopathy: A Retrospective Study , 2020, Journal of diabetes research.

[10]  Jennifer I. Lim,et al.  Diabetic Retinopathy Preferred Practice Pattern®. , 2019, Ophthalmology.

[11]  Qifu Li,et al.  Standards of medical care for type 2 diabetes in China 2019 , 2019, Diabetes/metabolism research and reviews.

[12]  Alan W. Stitt,et al.  Neurodegeneration in diabetic retinopathy: does it really matter? , 2018, Diabetologia.

[13]  Y. Bao,et al.  Abdominal subcutaneous adipose tissue: a favorable adipose depot for diabetes? , 2018, Cardiovascular Diabetology.

[14]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[15]  E. Finkelstein,et al.  Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes , 2017, JAMA.

[16]  A. Dunah,et al.  Anti-inflammatory effects of astroglial α7 nicotinic acetylcholine receptors are mediated by inhibition of the NF-κB pathway and activation of the Nrf2 pathway , 2017, Journal of Neuroinflammation.

[17]  Venkata Ravi Gutlapalli,et al.  Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies , 2017, Journal of Clinical Neuroscience.

[18]  C. Rochitte,et al.  Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial. , 2017, JCI insight.

[19]  Jennifer K. Sun,et al.  Diabetic Retinopathy: A Position Statement by the American Diabetes Association , 2017, Diabetes Care.

[20]  Noemi Lois,et al.  The progress in understanding and treatment of diabetic retinopathy , 2016, Progress in Retinal and Eye Research.

[21]  R. León,et al.  Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. , 2015, Biochemical pharmacology.

[22]  E. Oda.  Associations between serum cholinesterase and incident hyper-LDL cholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia as well as changes in lipid levels in a health screening population. , 2015, Atherosclerosis.

[23]  K. K. Sato,et al.  Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study , 2014, Clinical endocrinology.

[24]  C. Casanova,et al.  Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma. , 2013, Investigative ophthalmology & visual science.

[25]  F. Contaldo,et al.  Butyrylcholinesterase as a prognostic marker: a review of the literature , 2012, Journal of cachexia, sarcopenia and muscle.

[26]  M. Schneck,et al.  Neurodegenerative differences in the retinas of male and female patients with type 2 diabetes. , 2012, Investigative ophthalmology & visual science.

[27]  Norbert Pfeiffer,et al.  Identification of the muscarinic acetylcholine receptor subtype mediating cholinergic vasodilation in murine retinal arterioles. , 2011, Investigative ophthalmology & visual science.

[28]  Ciro Costagliola,et al.  Predicting the risk of diabetic retinopathy in type 2 diabetic patients. , 2011, Journal of diabetes and its complications.

[29]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[30]  Michael J. Pencina,et al.  Comments on ‘Integrated discrimination and net reclassification improvements—Practical advice’ , 2008 .

[31]  M. Schetinger,et al.  Serum cholinesterase activity in diabetes and associated pathologies. , 2006, Diabetes research and clinical practice.

[32]  M. Mathews,et al.  Relationship between serum butyrylcholinesterase and the metabolic syndrome. , 2005, Clinical biochemistry.

[33]  C. Delporte,et al.  Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. , 2004, Endocrinology.

[34]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[35]  M. Mesulam,et al.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.

[36]  S. Brimijoin,et al.  Butyrylcholinesterase in Human Brain and Acetylcholinesterase in Human Plasma: Trace Enzymes Measured by Two‐Site Immunoassay , 1988, Journal of neurochemistry.

[37]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[38]  G. Siest,et al.  Total cholinesterase in plasma: biological variations and reference limits. , 1985, Clinical chemistry.

[39]  M. Pencina,et al.  A SAS ® Macro to Compute Added Predictive Ability of New Markers Predicting a Dichotomous Outcome , 2010 .

[40]  Y. Terauchi,et al.  Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. , 2007, Internal medicine.

[41]  S. Patel,et al.  Relationship between age and plasma esterases. , 2001, Age and ageing.

[42]  A. Vitelli,et al.  [Epidemiology of diabetic retinopathy]. , 1988, Minerva endocrinologica.